Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier

被引:101
作者
Paris, Daniel [1 ]
Bachmeier, Corbin [1 ]
Patel, Nikunj [1 ]
Quadros, Amita [1 ]
Volmar, Claude-Henry [1 ]
Laporte, Vincent [1 ]
Ganey, Jim [1 ]
Beaulieu-Abdelahad, David [1 ]
Ait-Ghezala, Ghania [1 ]
Crawford, Fiona [1 ]
Mullan, Michael J. [1 ]
机构
[1] Roskamp Inst, Sarasota, FL 34243 USA
关键词
AMYLOID-PRECURSOR-PROTEIN; CALCIUM-CHANNEL BLOCKERS; FACTOR-KAPPA-B; COGNITIVE DECLINE; HYPERTENSIVE PATIENTS; NILVADIPINE PREVENTS; CEREBROSPINAL-FLUID; SYST-EUR; PEPTIDE; TRANSPORT;
D O I
10.2119/molmed.2010.00180
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Several large population-based or clinical trial studies have suggested that certain dihydropyridine (DHP) L-type calcium channel blockers (CCBs) used for the treatment of hypertension may confer protection against the development of Alzheimer disease (AD). However, other studies with drugs of the same class have shown no beneficial clinical effects. To determine whether certain DHPs are able to impact underlying disease processes in AD (specifically the accumulation of the Alzheimer A beta peptide), we investigated the effect of several antihypertensive DHPs and non-DHP CCBs on A beta production. Among the antihypertensive DHPs tested, a few, including nilvadipine, nitrendipine and amlodipine inhibited A beta production in vitro, whereas others had no effect or raised A beta levels. In vivo, nilvadipine and nitrendipine acutely reduced brain A beta levels in a transgenic mouse model of AD (Tg PS1/APPsw) and improved A beta clearance across the blood-brain barrier (BBB), whereas amlodipine and nifedipine were ineffective showing that the A beta-lowering activity of the DHPs is independent of their antihypertensive activity. Chronic oral treatment with nilvadipine decreased A beta burden in the brains of Tg APPsw (Tg2576) and Tg PS1/APPsw mice, and also improved learning abilities and spatial memory. Our data suggest that the clinical benefit conferred by certain antihypertensive DHPs against AD is unrelated to their antihypertensive activity, but rely on their ability to lower brain A beta accumulation by affecting both A beta production and A beta clearance across the BBB. (C) 2011 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2010.00180
引用
收藏
页码:149 / 162
页数:14
相关论文
共 57 条
[1]  
[Anonymous], 1991, JAMA, V265, P3255
[2]   Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier [J].
Bachmeier, Corbin ;
Mullan, Michael ;
Paris, Daniel .
CYTOTECHNOLOGY, 2010, 62 (06) :519-529
[3]   Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo [J].
Bateman, Randall J. ;
Munsell, Ling Y. ;
Morris, John C. ;
Swarm, Robert ;
Yarasheski, Kevin E. ;
Holtzman, David M. .
NATURE MEDICINE, 2006, 12 (07) :856-861
[4]   Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease [J].
Bell, Robert D. ;
Zlokovic, Berislav V. .
ACTA NEUROPATHOLOGICA, 2009, 118 (01) :103-113
[5]  
Bellew KM, 2004, ALZ DIS ASSOC DIS, V18, P208
[6]   NFκB-dependent control of BACE1 promoter transactivation by Aβ42 [J].
Buggia-Prevot, Virginie ;
Sevalle, Jean ;
Rossner, Steffen ;
Checler, Frederic .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (15) :10037-10047
[7]   An Overview of APP Processing Enzymes and Products [J].
Chow, Vivian W. ;
Mattson, Mark P. ;
Wong, Philip C. ;
Gleichmann, Marc .
NEUROMOLECULAR MEDICINE, 2010, 12 (01) :1-12
[8]   Alzheimer's disease: strategies for disease modification [J].
Citron, Martin .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (05) :387-398
[9]   LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms [J].
Deane, R ;
Wu, ZH ;
Sagare, A ;
Davis, J ;
Yan, SD ;
Hamm, K ;
Xu, F ;
Parisi, M ;
LaRue, B ;
Hu, HW ;
Spijkers, P ;
Guo, H ;
Song, XM ;
Lenting, PJ ;
Van Nostrand, WE ;
Zlokovic, BV .
NEURON, 2004, 43 (03) :333-344
[10]   Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimer's Disease [J].
Deane, R. ;
Bell, R. D. ;
Sagare, A. ;
Zlokovic, B. V. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (01) :16-30